Dihexa

Unregulated

Also known as: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, PMI 6

Nootropic & Cognitive

Last reviewed: April 28, 2026

An angiotensin IV analog peptide developed at Washington State University that has shown extraordinary cognitive-enhancing properties in animal models. In preclinical studies, dihexa was reported to be up to 10 million times more potent than BDNF at promoting new synapse formation, making it one of the most discussed nootropic peptides in the biohacking community.

Mechanism of Action

Binds to hepatocyte growth factor (HGF) receptor (c-Met), potentiating HGF/c-Met signaling which promotes synaptogenesis, dendritic spine formation, and neuronal connectivity. This mechanism is distinct from traditional nootropics and operates through growth factor pathways rather than neurotransmitter modulation.

Common Uses

  • Cognitive enhancement (investigational)
  • Memory and learning support
  • Neuroprotection research
  • Alzheimer's disease research

Known Risks

  • No human clinical trials — safety profile unknown
  • Theoretical cancer risk (HGF/c-Met pathway involved in tumor growth)
  • Long-term effects completely unstudied in humans
  • Quality control concerns with research chemical sourcing

Regulatory Status

Unregulated

No FDA status. Purely a research compound with preclinical data only. No IND application or clinical trials registered. Available only as a research chemical. The HGF/c-Met mechanism raises theoretical oncology concerns that would need to be addressed before clinical development.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Oral or sublingual (research use only)

Typical Dose

10–40 mg (anecdotal — no clinical dosing established)

Frequency

Once daily

Cycle Length

Unknown — no clinical data

No human clinical trials exist. All dosing information is anecdotal from self-experimenters. The theoretical cancer risk from HGF/c-Met activation should be seriously considered. Not recommended without medical supervision.

Related Compounds

Research References

Related Articles

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.